Risteys · G6

Endpoint definition steps	FinnGen
Phenotype data	520210
1. Apply sex-specific rule None	520210
2. Check conditions None	520210
3. Check pre-conditions, main-only, mode, registry filters Registry filters: Hospital discharge: ICD-10 — G52.0 Hospital discharge: ICD-9 — 3520 Hospital discharge: ICD-8 — 35600 Cause of death: ICD-10 — G52.0 Cause of death: ICD-9 — 3520 Cause of death: ICD-8 — 35600 2 out of 7 registries used, show all original rules.	37
4. Check minimum number of events None	37
5. Include endpoints None	37
6. Filter based on genotype QC (FinnGen only)	37

Summary Statistics

↥

-FinRegistry-

Key figures

	All	Female	Male
Number of individuals
Whole population	260	154	103
Only index persons	228	133	95
Unadjusted period prevalence (%)
Whole population	0.00	0.00	0.00
Only index persons	0.00	0.00	0.00
Median age at first event (years)
Whole population	54.60	56.07	52.41
Only index persons	53.84	54.68	52.66

-FinnGen-

Key figures

	All	Female	Male
Number of individuals	37	25	12
Unadjusted period prevalence (%)	0.01	0.01	0.01
Median age at first event (years)	55.36	53.68	58.86

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

No data

-FinnGen-

Cumulative Incidence Function

Not a core endpoint, no data to show.

CodeWAS (R11)

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log₁₀(p-value) ≥ 6.

No data available

LabWAS

↥

(ID) Name

N Cases

N Controls

-log₁₀(p)

cases

controls

cases

controls

unit

-log₁₀(p)

N cases

N controls

(43054903) Holo-transcobalamin II [Moles/volume] in Serum

111

2.75

2.29

1.8

2.0

95.2

93.3

pmol/l

0.09

(40768797) Stomach Pathology biopsy report

2.80

1.59

1.2

—

(3013512) EKG study

2.29

1.52

4.1

4.0

—

(43054914) Glucose tolerance 2 hours panel - Serum or Plasma

2.72

1.19

1.4

2.0

—

(3022145) Colonoscopy Study observation

2.54

1.18

1.4

—

(3013707) Erythrocyte sedimentation rate by Westergren method

220

2.12

1.12

3.7

4.1

7.6

10.9

mm/h

1.09

196

(3000492) Spirometry study

2.46

1.07

1.4

—

(3015736) pH of Urine

114

1.91

1.04

2.2

2.9

—

(3042936) Bacteria identified in Isolate by Culture

2.16

1.03

2.0

1.4

—

(3037467) Urinalysis macro (dipstick) panel - Urine

196

1.85

0.90

3.5

4.2

—

(3022217) INR in Platelet poor plasma by Coagulation assay

1.97

0.83

46.5

19.3

—

1.6

—

(3035995) Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma

235

1.78

0.81

8.6

6.6

100.0

78.4

u/l

0.78

213

(3009201) Thyrotropin [Units/volume] in Serum or Plasma

279

2.08

0.80

4.3

4.7

1.7

2.0

mu/l

1.05

243

(3019225) pH of Specimen

2.25

0.78

2.2

4.1

—

(40768804) Tissue Pathology biopsy report

123

1.71

0.77

2.6

2.1

—

(40761535) Cells panel - Urine sediment

2.15

0.76

2.4

3.6

—

(3029287) Urinalysis microscopic panel [#/volume] - Urine by Automated count

1.71

0.68

3.3

3.1

—

(3009542) Hematocrit [Volume Fraction] of Blood

283

1.96

0.66

16.8

13.0

41.5

39.4

1.45

202

(3004410) Hemoglobin A1c/Hemoglobin.total in Blood

282

1.99

0.66

5.3

5.1

39.2

mmol/mol

0.01

261

(3003785) Carcinoembryonic Ag [Mass/volume] in Serum or Plasma

1.77

0.64

5.2

3.4

35.2

158.3

ug/l

—

(40763086) Leukocyte esterase [Presence] in Urine by Automated test strip

119

1.61

0.62

2.7

3.4

—

(3045783) Sodium and Potassium panel [Moles/volume] - Serum or Plasma

1.59

0.54

6.7

6.3

—

(3023368) Bacteria identified in Blood by Culture

1.64

0.54

6.2

4.2

—

(3007853) Bacteria identified in Skin by Aerobe culture

1.71

0.45

2.6

1.6

—

(3008486) Thyroxine (T4) free [Moles/volume] in Serum or Plasma

228

1.47

0.41

3.8

3.9

14.4

14.7

pmol/l

0.30

196

(3002256) Pathology report gross observation

1.55

0.38

1.8

1.1

—

(3000494) Fungus identified in Specimen by Culture

1.55

0.38

1.7

1.4

—

(706163) SARS-CoV-2 (COVID-19) RNA [Presence] in Respiratory system specimen by NAA with probe detection

188

0.74

0.32

2.9

3.2

—

(3033658) Prothrombin time (PT) actual/Normal

1.40

0.31

4.6

3.6

88.5

94.2

—

(3011397) Hemoglobin [Presence] in Urine by Test strip

1.37

0.31

2.8

3.2

—

(3026008) Bacteria identified in Urine by Culture

1.38

0.28

2.8

—

(3048689) Calprotectin [Mass/mass] in Stool

1.29

0.23

1.4

1.6

81.6

189.3

ug/g

—

(3041096) Erythrocytes [Presence] in Urine by Automated

1.32

0.22

2.4

3.1

—

(3008898) HLA-B27 [Presence]

0.00

0.22

0.0

1.3

—

(3021584) Pregnancy associated plasma protein A [Units/volume] in Serum or Plasma

0.00

0.22

0.0

1.5

—

(3050129) First trimester maternal screen panel - Serum or Plasma

0.00

0.22

0.0

1.3

—

(3020891) Body temperature

0.00

0.22

0.0

5.4

—

(3000620) Complement C3 [Mass/volume] in Serum or Plasma

0.00

0.22

0.0

1.2

—

1.3

—

(3004716) Salmonella sp identified in Stool by Organism specific culture

0.00

0.20

0.0

1.4

—

(3018006) Microscopic observation [Identifier] in Cervix by Cyto stain.thin prep

0.73

0.19

1.2

1.3

—

(40764999) Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI)

284

1.30

0.17

14.1

11.6

83.8

79.8

ml/min/173m2

0.45

229

(46235355) HIV 1 and 2 tests - Meaningful Use set

1.13

0.10

3.0

2.0

—

(3044938) Influenza virus A RNA [Presence] in Specimen by NAA with probe detection

1.13

0.10

1.8

2.0

—

(3001079) Blood group antibody screen [Presence] in Serum or Plasma

137

1.16

0.09

3.1

3.9

—

(36304419) Bacteria [Presence] in Urine

0.82

0.08

5.0

2.8

—

(40758558) Short blood count panel - Blood

0.79

0.08

9.0

5.4

—

(1761868) Lipid panel - Serum or Plasma

1.09

0.01

3.0

2.4

—

(3018010) Neutrophils/100 leukocytes in Blood

127

1.04

0.00

4.1

5.8

62.1

57.2

0.76

118

(3022096) Basophils/100 leukocytes in Blood

124

0.95

0.00

4.3

6.1

0.6

0.05

115

(3044889) 12 lead EKG panel

214

0.96

0.00

4.8

3.4

—

(3006504) Eosinophils/100 leukocytes in Blood

128

1.02

0.00

4.1

6.0

2.6

2.7

0.12

119

(3019069) Monocytes/100 leukocytes in Blood

129

1.01

0.00

4.4

6.2

7.4

8.5

0.68

120

(3002030) Lymphocytes/100 leukocytes in Blood

132

0.98

0.00

4.2

6.0

24.5

28.9

0.72

121

(3043238) Trisomy 21 risk [Likelihood] in Fetus

0.00

0.0

1.6

—

(3029511) Human papilloma virus DNA [Presence] in Specimen by NAA with probe detection

0.00

0.0

1.8

—

(46235831) Pregnancy associated plasma protein A [Multiple of the median] adjusted in Serum or Plasma

0.00

0.0

1.4

—

(3044640) Blood type and Crossmatch panel - Blood

0.99

0.00

3.1

2.2

—

(3010421) pH of Blood

0.00

0.0

7.8

—

7.4

—

(3019145) Choriogonadotropin.beta subunit free [Mass/volume] in Serum or Plasma

0.00

0.0

1.8

—

(3013290) Carbon dioxide [Partial pressure] in Blood

0.00

0.0

7.6

—

5.0

—

(3023150) Myeloperoxidase Ab [Units/volume] in Serum

0.00

0.0

3.2

—

(3049207) Fetal Trisomy 21 risk [Likelihood] Based on maternal age

0.00

0.0

1.4

—

(40763531) Fetal Nuchal fold [Multiple of the median] Thickness adjusted for maternal weight

0.00

0.0

1.4

—

(3008909) Norovirus RNA [Presence] in Stool by NAA with probe detection

0.00

0.0

1.8

—

(3027315) Oxygen [Partial pressure] in Blood

0.00

0.0

7.6

—

7.8

—

(40768800) Prostate Pathology biopsy report

0.00

0.0

1.4

—

(3003191) Choriogonadotropin (pregnancy test) [Presence] in Serum or Plasma

0.00

0.0

1.4

—

(3011363) Streptococcus pneumoniae Ag [Presence] in Urine

0.00

0.0

1.0

—

(3009214) Lutropin [Units/volume] in Serum or Plasma

0.00

0.0

1.4

—

9.9

—

(3003694) ABO and Rh group [Type] in Blood

0.98

0.00

1.4

1.5

—

(3004248) Sex hormone binding globulin [Moles/volume] in Serum or Plasma

0.00

0.0

1.2

—

43.4

—

(3008714) Choriogonadotropin [Multiple of the median] adjusted in Serum or Plasma

0.00

0.0

1.4

—

(1175715) Chlamydophila pneumoniae IgM Ab [Presence] in Serum by Immunoassay

0.00

0.0

1.0

—

(42870588) Differential panel, method unspecified - Blood

0.90

0.00

4.8

5.5

—

(3011985) Renin [Units/volume] in Plasma

0.00

0.0

1.0

—

15.5

—

(40768806) Pleura Pathology biopsy report

0.00

0.0

1.6

—

(3039162) Centromere protein B Ab [Units/volume] in Serum

0.00

0.0

1.4

—

(3009340) Metanephrine [Moles/volume] in Serum or Plasma

0.00

0.0

1.2

—

(3032155) Metanephrine Free [Moles/volume] in Serum or Plasma

0.00

0.0

1.0

—

(3030408) 3-Methoxytyramine [Moles/volume] in Serum or Plasma

0.00

0.0

1.2

—

(3024172) Erythropoietin (EPO) [Units/volume] in Serum or Plasma

0.00

0.0

1.2

—

13.1

—

(3047007) Chlamydophila sp Ab [Presence] in Serum

0.00

0.0

1.0

—

(3025018) Bordetella pertussis Ab [Titer] in Serum

0.00

0.0

1.0

—

(3005570) Glucose [Moles/volume] in Urine

0.00

0.0

2.4

—

(3042111) Morphology [Interpretation] in Bone marrow Narrative

0.00

0.0

1.0

—

(3024135) Streptococcus.beta-hemolytic [Presence] in Throat by Organism specific culture

1.02

0.00

1.3

1.5

—

(46236098) ABO and Rh group [Type] in Blood by Confirmatory method

1.02

0.00

3.0

2.1

—

(3023511) Choriogonadotropin [Units/volume] in Urine

0.00

0.0

1.0

—

(1616796) Gas panel - Central venous blood

0.00

0.0

6.8

—

(42529200) Cancer Ag 15-3 [Units/volume] in Serum or Plasma by Immunoassay

0.00

0.0

2.0

—

37.8

—

(3014765) Yersinia sp identified in Stool by Organism specific culture

0.00

-0.00

0.0

1.3

—

(3021387) Prolactin [Units/volume] in Serum or Plasma

0.00

-0.00

0.0

2.4

—

398.1

—

(42529406) Shigella sp [Presence] in Stool by Culture

0.00

-0.00

0.0

1.3

—

(4034850)

0.00

-0.00

0.0

8.8

—

(3006418) Campylobacter sp identified in Tissue by Organism specific culture

0.00

-0.00

0.0

1.3

—

(3037756) Immunofixation for Serum or Plasma

0.00

-0.00

0.0

1.4

—

Mortality – FinRegistry

↥

Association

Association between endpoint G6_DISOLF and mortality.

Females

No data

Males

No data

Mortality risk

Mortality risk for people of age

years, who have G6_DISOLF.

N-year risk	Females	Males
1	No data	No data
5	No data	No data
10	No data	No data
15	No data	No data
20	No data	No data

Relationships between endpoints

↥

Index endpoint: G6_DISOLF – Disorders of olfactory nerve

GWS hits: -

Endpoint

Case Overlap

Survival Analysis

Genetic Correlations

Genetic Signals

N (Jaccard index)

HR [CI]

rg [CI]

Hits

Coloc Hits

FinRegistry

FinnGen

FinRegistry

FinnGen

Loading data

NAME	G6_DISOLF
CONTROL_EXCLUDE	G6_NERPLEX
CONTROL_PRECONDITIONS
CONTROL_CONDITIONS
SEX
INCLUDE
PRE_CONDITIONS
CONDITIONS
OUTPAT_ICD
OUTPAT_OPER
HD_MAINONLY
HD_ICD_10_ATC
HD_ICD_10	G520
HD_ICD_9	3520
HD_ICD_8	35600
HD_ICD_10_EXCL
HD_ICD_9_EXCL
HD_ICD_8_EXCL
COD_MAINONLY
COD_ICD_10	G520
COD_ICD_9	3520
COD_ICD_8	35600
COD_ICD_10_EXCL
COD_ICD_9_EXCL
COD_ICD_8_EXCL
OPER_NOM
OPER_HL
OPER_HP1
OPER_HP2
KELA_REIMB
KELA_REIMB_ICD
KELA_ATC_NEEDOTHER
KELA_ATC
KELA_VNRO_NEEDOTHER
KELA_VNRO
CANC_TOPO
CANC_TOPO_EXCL
CANC_MORPH
CANC_MORPH_EXCL
CANC_BEHAV

Disorders of olfactory nerve

Endpoint definition

Endpoint definition steps

FinnGen

Phenotype data

1. Apply sex-specific rule

2. Check conditions

3. Check pre-conditions, main-only, mode, registry filters

4. Check minimum number of events

5. Include endpoints

6. Filter based on genotype QC (FinnGen only)

Similar endpoints

Case counts by codes

Summary Statistics

-FinRegistry-

Key figures

-FinnGen-

Key figures

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

-FinnGen-

Cumulative Incidence Function

CodeWAS (R11)

LabWAS

Mortality – FinRegistry

Association

Females

Males

Mortality risk

Relationships between endpoints